RU EN

Mon.-Fri.: 1000-1900

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

«A.Zalesov & Partners» Patent & Law Firm is a full-service IP law firm that gives IP advice, handles litigation (patents, trademarks and designs) and provides services in patent, design and trademark prosecution in the Russian Patent and Trademark Office and the Eurasian Patent Office. We handle our international clients' patent and trademark portfolios (including Madrid and Hague Systems of trademark and design registration) in Russia as well as in the neighboring countries, including the countries of the Eurasian Custom and Economic Union. Twenty years of experience in conducting patent and trademark disputes between leading players in the relevant markets in Russia and abroad enables us to give verified practical advice on IP protection, invalidation and enforcement strategy.

 

In focus

On the freezing of the Hague Act of 1960 starting from January 2025

As of 2025, the Hague system will be based exclusively on the Geneva Act of 1999.

02.12.2024

Patent Attorney Julia Dutikova made a report on the issues of practical use of new requirements for pharmaceutical patent applications at the «Intellectual Rights: Challenges of the 21st Century» Conference

The VI International Research-to-Practice Conference «Intellectual Rights: Challenges of the 21st Century» is being held at the National Research Tomsk State University on November 14-16, 2024.

15.11.2024

«A.Zalesov & Partners» have procured a seven-fold reduction of the damages awarded from the client in a dispute on the infringement of two patents for the medication for cancer treatment

A foreign company filed an action against the client of «A.Zalesov & Partners» Patent & Law Firm - Pharmasyntez Group of Companies, one of the top leading biopharmaceutical companies - for the infringement of two Russian patents claiming the recovery of damages and the prohibition of the sale of a generic (a medication for the treatment of cancer) until 2026.

15.11.2024